Hypothalamic control of growth hormone (GH) secretion in type i diabetic men: Effect of the combined administration of gh-releasing hormone and hexarelin, a novel GHRP-6 analog
Insulin dependent (type I) diabetic patients show abnormal growth hormone (GH) secretion. Hexarelin is an analog of GHRP-6 which releases GH in part via somatostatin inhibition. The aim of our study was to evaluate the effects of hexarelin and GHRH, administered either alone or in combination, on GH...
Gespeichert in:
| Veröffentlicht in: | Endocrine research 1996-01, Vol.22 (2), p.159-174 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 174 |
|---|---|
| container_issue | 2 |
| container_start_page | 159 |
| container_title | Endocrine research |
| container_volume | 22 |
| creator | Giustina, A. Desenzani, P. Perini, P. Deghenghi, R. Bugari, G. Wehrenberg, W. B. Giustina, G. |
| description | Insulin dependent (type I) diabetic patients show abnormal growth hormone (GH) secretion. Hexarelin is an analog of GHRP-6 which releases GH in part via somatostatin inhibition. The aim of our study was to evaluate the effects of hexarelin and GHRH, administered either alone or in combination, on GH secretion in 10 type I diabetic and 7 normal men. All the subjects were administered: 1) human GHRH (1-29)NH2 100 μg iv bolus at 0 min; 2) hexarelin 100 μg iv bolus at 0 min; 3) hexarelin 100 μg + hGHRH 100 μg iv bolus at 0 min. In type I diabetic patients significantly greater GH responses to GHRH and hexarelin have been observed with normal subjects. Hexarelin caused a significantly (p |
| doi_str_mv | 10.1080/07435809609030505 |
| format | Article |
| fullrecord | <record><control><sourceid>informahealthcare_infor</sourceid><recordid>TN_cdi_informahealthcare_journals_10_1080_07435809609030505</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1080_07435809609030505</sourcerecordid><originalsourceid>FETCH-LOGICAL-c401t-983a5bc25808c75950c5137b5df2cb7a53e9cf1148373496712b63551a9b20b43</originalsourceid><addsrcrecordid>eNp9kNFqFDEUhoModa0-gBdCLhUcPZlMZibqTSl1VygootfDSSbZSZlJliS13bfyEc26pSBCrwL58v055yfkJYN3DHp4D13DRQ-yBQkcBIhHZMUEr6umhvYxWR14VR7AU_IspSsAxgH4CTnpOylbKVbk92a_C3nCGRenqQ4-xzDTYOk2hps80SnEJXhDX683b2gyOprsgqfO07zfGero6FCVO00X4z_QC2uNzgc_T6bELcp5M1IcF-ddyhH_2of4qYpmNpic395_gn6kk7nFQpx_S5H68MvMdL35_q1qC8U5bJ-TJxbnZF7cnafk5-eLH-eb6vLr-sv52WWlG2C5kj1HoXRdlu91J6QALRjvlBhtrVWHghupLWNNzzveyLZjtWq5EAylqkE1_JSwY66OIaVo7LCLbsG4HxgMh_KH_8ovzqujs7tWixnvjbu2C_905M7bsjLehDiPQ8b9HKKN6LVLA38o_uM_-mRwzpMudQ1X4TqWetIDw_0BwjSlgg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Hypothalamic control of growth hormone (GH) secretion in type i diabetic men: Effect of the combined administration of gh-releasing hormone and hexarelin, a novel GHRP-6 analog</title><source>Taylor & Francis</source><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><creator>Giustina, A. ; Desenzani, P. ; Perini, P. ; Deghenghi, R. ; Bugari, G. ; Wehrenberg, W. B. ; Giustina, G.</creator><creatorcontrib>Giustina, A. ; Desenzani, P. ; Perini, P. ; Deghenghi, R. ; Bugari, G. ; Wehrenberg, W. B. ; Giustina, G.</creatorcontrib><description>Insulin dependent (type I) diabetic patients show abnormal growth hormone (GH) secretion. Hexarelin is an analog of GHRP-6 which releases GH in part via somatostatin inhibition. The aim of our study was to evaluate the effects of hexarelin and GHRH, administered either alone or in combination, on GH secretion in 10 type I diabetic and 7 normal men. All the subjects were administered: 1) human GHRH (1-29)NH2 100 μg iv bolus at 0 min; 2) hexarelin 100 μg iv bolus at 0 min; 3) hexarelin 100 μg + hGHRH 100 μg iv bolus at 0 min. In type I diabetic patients significantly greater GH responses to GHRH and hexarelin have been observed with normal subjects. Hexarelin caused a significantly (p<0.05) greater GH response as compared to GHRH in both diabetic and control subjects. After the administration of hexarelin+GHRH, a significant increase in both GH absolute and peak levels as compared to hexarelin or GHRH alone was found in all the subjects. However, the GH responses to the combined stimuli were not significantly different in diabetics as compared to normals; moreover, the interaction of GHRH and hexarelin was synergistic in controls and additive in diabetics. We hypothesize that a reduction in the hypothalamic somatostatin inhibitory tone combined with increased pituitary GH production may be responsible for the pattern of the GH responses to hexarelin and GHRH observed in our type I diabetic patients.</description><identifier>ISSN: 0743-5800</identifier><identifier>EISSN: 1532-4206</identifier><identifier>DOI: 10.1080/07435809609030505</identifier><identifier>PMID: 8799695</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Adult ; Blood Glucose - metabolism ; Diabetes Mellitus, Type 1 - physiopathology ; Drug Synergism ; Growth Hormone-Releasing Hormone - administration & dosage ; Growth Hormone-Releasing Hormone - pharmacology ; Human Growth Hormone - secretion ; Humans ; Hypothalamus - physiopathology ; Kinetics ; Male ; Oligopeptides - administration & dosage ; Oligopeptides - pharmacology</subject><ispartof>Endocrine research, 1996-01, Vol.22 (2), p.159-174</ispartof><rights>1996 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1996</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c401t-983a5bc25808c75950c5137b5df2cb7a53e9cf1148373496712b63551a9b20b43</citedby><cites>FETCH-LOGICAL-c401t-983a5bc25808c75950c5137b5df2cb7a53e9cf1148373496712b63551a9b20b43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/07435809609030505$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/07435809609030505$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,59620,59726,60409,60515,61194,61229,61375,61410</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8799695$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giustina, A.</creatorcontrib><creatorcontrib>Desenzani, P.</creatorcontrib><creatorcontrib>Perini, P.</creatorcontrib><creatorcontrib>Deghenghi, R.</creatorcontrib><creatorcontrib>Bugari, G.</creatorcontrib><creatorcontrib>Wehrenberg, W. B.</creatorcontrib><creatorcontrib>Giustina, G.</creatorcontrib><title>Hypothalamic control of growth hormone (GH) secretion in type i diabetic men: Effect of the combined administration of gh-releasing hormone and hexarelin, a novel GHRP-6 analog</title><title>Endocrine research</title><addtitle>Endocr Res</addtitle><description>Insulin dependent (type I) diabetic patients show abnormal growth hormone (GH) secretion. Hexarelin is an analog of GHRP-6 which releases GH in part via somatostatin inhibition. The aim of our study was to evaluate the effects of hexarelin and GHRH, administered either alone or in combination, on GH secretion in 10 type I diabetic and 7 normal men. All the subjects were administered: 1) human GHRH (1-29)NH2 100 μg iv bolus at 0 min; 2) hexarelin 100 μg iv bolus at 0 min; 3) hexarelin 100 μg + hGHRH 100 μg iv bolus at 0 min. In type I diabetic patients significantly greater GH responses to GHRH and hexarelin have been observed with normal subjects. Hexarelin caused a significantly (p<0.05) greater GH response as compared to GHRH in both diabetic and control subjects. After the administration of hexarelin+GHRH, a significant increase in both GH absolute and peak levels as compared to hexarelin or GHRH alone was found in all the subjects. However, the GH responses to the combined stimuli were not significantly different in diabetics as compared to normals; moreover, the interaction of GHRH and hexarelin was synergistic in controls and additive in diabetics. We hypothesize that a reduction in the hypothalamic somatostatin inhibitory tone combined with increased pituitary GH production may be responsible for the pattern of the GH responses to hexarelin and GHRH observed in our type I diabetic patients.</description><subject>Adult</subject><subject>Blood Glucose - metabolism</subject><subject>Diabetes Mellitus, Type 1 - physiopathology</subject><subject>Drug Synergism</subject><subject>Growth Hormone-Releasing Hormone - administration & dosage</subject><subject>Growth Hormone-Releasing Hormone - pharmacology</subject><subject>Human Growth Hormone - secretion</subject><subject>Humans</subject><subject>Hypothalamus - physiopathology</subject><subject>Kinetics</subject><subject>Male</subject><subject>Oligopeptides - administration & dosage</subject><subject>Oligopeptides - pharmacology</subject><issn>0743-5800</issn><issn>1532-4206</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kNFqFDEUhoModa0-gBdCLhUcPZlMZibqTSl1VygootfDSSbZSZlJliS13bfyEc26pSBCrwL58v055yfkJYN3DHp4D13DRQ-yBQkcBIhHZMUEr6umhvYxWR14VR7AU_IspSsAxgH4CTnpOylbKVbk92a_C3nCGRenqQ4-xzDTYOk2hps80SnEJXhDX683b2gyOprsgqfO07zfGero6FCVO00X4z_QC2uNzgc_T6bELcp5M1IcF-ddyhH_2of4qYpmNpic395_gn6kk7nFQpx_S5H68MvMdL35_q1qC8U5bJ-TJxbnZF7cnafk5-eLH-eb6vLr-sv52WWlG2C5kj1HoXRdlu91J6QALRjvlBhtrVWHghupLWNNzzveyLZjtWq5EAylqkE1_JSwY66OIaVo7LCLbsG4HxgMh_KH_8ovzqujs7tWixnvjbu2C_905M7bsjLehDiPQ8b9HKKN6LVLA38o_uM_-mRwzpMudQ1X4TqWetIDw_0BwjSlgg</recordid><startdate>19960101</startdate><enddate>19960101</enddate><creator>Giustina, A.</creator><creator>Desenzani, P.</creator><creator>Perini, P.</creator><creator>Deghenghi, R.</creator><creator>Bugari, G.</creator><creator>Wehrenberg, W. B.</creator><creator>Giustina, G.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19960101</creationdate><title>Hypothalamic control of growth hormone (GH) secretion in type i diabetic men: Effect of the combined administration of gh-releasing hormone and hexarelin, a novel GHRP-6 analog</title><author>Giustina, A. ; Desenzani, P. ; Perini, P. ; Deghenghi, R. ; Bugari, G. ; Wehrenberg, W. B. ; Giustina, G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c401t-983a5bc25808c75950c5137b5df2cb7a53e9cf1148373496712b63551a9b20b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adult</topic><topic>Blood Glucose - metabolism</topic><topic>Diabetes Mellitus, Type 1 - physiopathology</topic><topic>Drug Synergism</topic><topic>Growth Hormone-Releasing Hormone - administration & dosage</topic><topic>Growth Hormone-Releasing Hormone - pharmacology</topic><topic>Human Growth Hormone - secretion</topic><topic>Humans</topic><topic>Hypothalamus - physiopathology</topic><topic>Kinetics</topic><topic>Male</topic><topic>Oligopeptides - administration & dosage</topic><topic>Oligopeptides - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giustina, A.</creatorcontrib><creatorcontrib>Desenzani, P.</creatorcontrib><creatorcontrib>Perini, P.</creatorcontrib><creatorcontrib>Deghenghi, R.</creatorcontrib><creatorcontrib>Bugari, G.</creatorcontrib><creatorcontrib>Wehrenberg, W. B.</creatorcontrib><creatorcontrib>Giustina, G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Endocrine research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giustina, A.</au><au>Desenzani, P.</au><au>Perini, P.</au><au>Deghenghi, R.</au><au>Bugari, G.</au><au>Wehrenberg, W. B.</au><au>Giustina, G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hypothalamic control of growth hormone (GH) secretion in type i diabetic men: Effect of the combined administration of gh-releasing hormone and hexarelin, a novel GHRP-6 analog</atitle><jtitle>Endocrine research</jtitle><addtitle>Endocr Res</addtitle><date>1996-01-01</date><risdate>1996</risdate><volume>22</volume><issue>2</issue><spage>159</spage><epage>174</epage><pages>159-174</pages><issn>0743-5800</issn><eissn>1532-4206</eissn><abstract>Insulin dependent (type I) diabetic patients show abnormal growth hormone (GH) secretion. Hexarelin is an analog of GHRP-6 which releases GH in part via somatostatin inhibition. The aim of our study was to evaluate the effects of hexarelin and GHRH, administered either alone or in combination, on GH secretion in 10 type I diabetic and 7 normal men. All the subjects were administered: 1) human GHRH (1-29)NH2 100 μg iv bolus at 0 min; 2) hexarelin 100 μg iv bolus at 0 min; 3) hexarelin 100 μg + hGHRH 100 μg iv bolus at 0 min. In type I diabetic patients significantly greater GH responses to GHRH and hexarelin have been observed with normal subjects. Hexarelin caused a significantly (p<0.05) greater GH response as compared to GHRH in both diabetic and control subjects. After the administration of hexarelin+GHRH, a significant increase in both GH absolute and peak levels as compared to hexarelin or GHRH alone was found in all the subjects. However, the GH responses to the combined stimuli were not significantly different in diabetics as compared to normals; moreover, the interaction of GHRH and hexarelin was synergistic in controls and additive in diabetics. We hypothesize that a reduction in the hypothalamic somatostatin inhibitory tone combined with increased pituitary GH production may be responsible for the pattern of the GH responses to hexarelin and GHRH observed in our type I diabetic patients.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>8799695</pmid><doi>10.1080/07435809609030505</doi><tpages>16</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0743-5800 |
| ispartof | Endocrine research, 1996-01, Vol.22 (2), p.159-174 |
| issn | 0743-5800 1532-4206 |
| language | eng |
| recordid | cdi_informahealthcare_journals_10_1080_07435809609030505 |
| source | Taylor & Francis; MEDLINE; Taylor & Francis Medical Library - CRKN |
| subjects | Adult Blood Glucose - metabolism Diabetes Mellitus, Type 1 - physiopathology Drug Synergism Growth Hormone-Releasing Hormone - administration & dosage Growth Hormone-Releasing Hormone - pharmacology Human Growth Hormone - secretion Humans Hypothalamus - physiopathology Kinetics Male Oligopeptides - administration & dosage Oligopeptides - pharmacology |
| title | Hypothalamic control of growth hormone (GH) secretion in type i diabetic men: Effect of the combined administration of gh-releasing hormone and hexarelin, a novel GHRP-6 analog |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T05%3A40%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-informahealthcare_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hypothalamic%20control%20of%20growth%20hormone%20(GH)%20secretion%20in%20type%20i%20diabetic%20men:%20Effect%20of%20the%20combined%20administration%20of%20gh-releasing%20hormone%20and%20hexarelin,%20a%20novel%20GHRP-6%20analog&rft.jtitle=Endocrine%20research&rft.au=Giustina,%20A.&rft.date=1996-01-01&rft.volume=22&rft.issue=2&rft.spage=159&rft.epage=174&rft.pages=159-174&rft.issn=0743-5800&rft.eissn=1532-4206&rft_id=info:doi/10.1080/07435809609030505&rft_dat=%3Cinformahealthcare_infor%3E10_1080_07435809609030505%3C/informahealthcare_infor%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/8799695&rfr_iscdi=true |